Serelaxin Elicits Bronchodilation and Enhances β-Adrenoceptor-mediated Airway Relaxation

Treatment with β-adrenoceptor agonists does not fully overcome the symptoms associated with severe asthma. Serelaxin elicits potent uterine and vascular relaxation via its cognate receptor, RXFP1, and nitric oxide (NO) signaling, and is being clinically evaluated for the treatment of acute heart fai...

Full description

Bibliographic Details
Main Authors: Maggie Lam, Simon G Royce, Chantal Donovan, Maria Jelinic, Laura J Parry, Chrishan S Samuel, Jane Elizabeth Bourke
Format: Article
Language:English
Published: Frontiers Media S.A. 2016-10-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:http://journal.frontiersin.org/Journal/10.3389/fphar.2016.00406/full
_version_ 1818606713446596608
author Maggie Lam
Simon G Royce
Chantal Donovan
Maria Jelinic
Laura J Parry
Chrishan S Samuel
Jane Elizabeth Bourke
author_facet Maggie Lam
Simon G Royce
Chantal Donovan
Maria Jelinic
Laura J Parry
Chrishan S Samuel
Jane Elizabeth Bourke
author_sort Maggie Lam
collection DOAJ
description Treatment with β-adrenoceptor agonists does not fully overcome the symptoms associated with severe asthma. Serelaxin elicits potent uterine and vascular relaxation via its cognate receptor, RXFP1, and nitric oxide (NO) signaling, and is being clinically evaluated for the treatment of acute heart failure. However, its direct bronchodilator efficacy has yet to be explored. Tracheal rings were prepared from male Sprague-Dawley rats (250-350g) and tricolor guinea pigs, and precision cut lung slices (PCLS) containing intrapulmonary airways were prepared from rats only. Recombinant human serelaxin (rhRLX) alone and in combination with rosiglitazone (PPARγ agonist; recently described as a novel dilator) or β-adrenoceptor agonists (isoprenaline, salbutamol) were added either to pre-contracted airways, or before contraction with methacholine or endothelin-1. Regulation of rhRLX responses by epithelial removal, indomethacin (cyclooxygenase inhibitor), L-NAME (nitric oxide synthase inhibitor), SQ22536 (adenylate cyclase inhibitor) and ODQ (guanylate cyclase inhibitor) were also evaluated. Immunohistochemistry was used to localize RXFP1 to airway epithelium and smooth muscle. rhRLX elicited relaxation in rat trachea and PCLS, more slowly than rosiglitazone or isoprenaline, but potentiated relaxation to both these dilators. It markedly increased β-adrenoceptor agonist potency in guinea pig trachea. rhRLX, rosiglitazone and isoprenaline pretreatment also inhibited the development of rat tracheal contraction. Bronchoprotection by rhRLX increased with longer pre-incubation time, and was partially reduced by epithelial removal, indomethacin and/or L-NAME. SQ22536 and ODQ also partially inhibited rhRLX-mediated relaxation in both intact and epithelial-denuded trachea. RXFP1 expression in airway was at higher levels in epithelium than smooth muscle.In summary, rhRLX elicits large and small airway relaxation via epithelial-dependent and -independent mechanisms, likely via RXFP1 activation and generation of nitric oxide, prostaglandins and cAMP/cGMP. rhRLX also enhanced responsiveness to other dilators, suggesting its potential as an alternative or add-on therapy for severe asthma.
first_indexed 2024-12-16T14:15:14Z
format Article
id doaj.art-d113ae669251420ab9a7c153343005fa
institution Directory Open Access Journal
issn 1663-9812
language English
last_indexed 2024-12-16T14:15:14Z
publishDate 2016-10-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Pharmacology
spelling doaj.art-d113ae669251420ab9a7c153343005fa2022-12-21T22:28:37ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122016-10-01710.3389/fphar.2016.00406223553Serelaxin Elicits Bronchodilation and Enhances β-Adrenoceptor-mediated Airway RelaxationMaggie Lam0Simon G Royce1Chantal Donovan2Maria Jelinic3Laura J Parry4Chrishan S Samuel5Jane Elizabeth Bourke6Monash UniversityMonash UniversityMonash UniversityThe University of MelbourneThe University of MelbourneMonash UniversityMonash UniversityTreatment with β-adrenoceptor agonists does not fully overcome the symptoms associated with severe asthma. Serelaxin elicits potent uterine and vascular relaxation via its cognate receptor, RXFP1, and nitric oxide (NO) signaling, and is being clinically evaluated for the treatment of acute heart failure. However, its direct bronchodilator efficacy has yet to be explored. Tracheal rings were prepared from male Sprague-Dawley rats (250-350g) and tricolor guinea pigs, and precision cut lung slices (PCLS) containing intrapulmonary airways were prepared from rats only. Recombinant human serelaxin (rhRLX) alone and in combination with rosiglitazone (PPARγ agonist; recently described as a novel dilator) or β-adrenoceptor agonists (isoprenaline, salbutamol) were added either to pre-contracted airways, or before contraction with methacholine or endothelin-1. Regulation of rhRLX responses by epithelial removal, indomethacin (cyclooxygenase inhibitor), L-NAME (nitric oxide synthase inhibitor), SQ22536 (adenylate cyclase inhibitor) and ODQ (guanylate cyclase inhibitor) were also evaluated. Immunohistochemistry was used to localize RXFP1 to airway epithelium and smooth muscle. rhRLX elicited relaxation in rat trachea and PCLS, more slowly than rosiglitazone or isoprenaline, but potentiated relaxation to both these dilators. It markedly increased β-adrenoceptor agonist potency in guinea pig trachea. rhRLX, rosiglitazone and isoprenaline pretreatment also inhibited the development of rat tracheal contraction. Bronchoprotection by rhRLX increased with longer pre-incubation time, and was partially reduced by epithelial removal, indomethacin and/or L-NAME. SQ22536 and ODQ also partially inhibited rhRLX-mediated relaxation in both intact and epithelial-denuded trachea. RXFP1 expression in airway was at higher levels in epithelium than smooth muscle.In summary, rhRLX elicits large and small airway relaxation via epithelial-dependent and -independent mechanisms, likely via RXFP1 activation and generation of nitric oxide, prostaglandins and cAMP/cGMP. rhRLX also enhanced responsiveness to other dilators, suggesting its potential as an alternative or add-on therapy for severe asthma.http://journal.frontiersin.org/Journal/10.3389/fphar.2016.00406/fullEpitheliumRelaxinTracheaairwayrosiglitazonebronchodilation
spellingShingle Maggie Lam
Simon G Royce
Chantal Donovan
Maria Jelinic
Laura J Parry
Chrishan S Samuel
Jane Elizabeth Bourke
Serelaxin Elicits Bronchodilation and Enhances β-Adrenoceptor-mediated Airway Relaxation
Frontiers in Pharmacology
Epithelium
Relaxin
Trachea
airway
rosiglitazone
bronchodilation
title Serelaxin Elicits Bronchodilation and Enhances β-Adrenoceptor-mediated Airway Relaxation
title_full Serelaxin Elicits Bronchodilation and Enhances β-Adrenoceptor-mediated Airway Relaxation
title_fullStr Serelaxin Elicits Bronchodilation and Enhances β-Adrenoceptor-mediated Airway Relaxation
title_full_unstemmed Serelaxin Elicits Bronchodilation and Enhances β-Adrenoceptor-mediated Airway Relaxation
title_short Serelaxin Elicits Bronchodilation and Enhances β-Adrenoceptor-mediated Airway Relaxation
title_sort serelaxin elicits bronchodilation and enhances β adrenoceptor mediated airway relaxation
topic Epithelium
Relaxin
Trachea
airway
rosiglitazone
bronchodilation
url http://journal.frontiersin.org/Journal/10.3389/fphar.2016.00406/full
work_keys_str_mv AT maggielam serelaxinelicitsbronchodilationandenhancesbadrenoceptormediatedairwayrelaxation
AT simongroyce serelaxinelicitsbronchodilationandenhancesbadrenoceptormediatedairwayrelaxation
AT chantaldonovan serelaxinelicitsbronchodilationandenhancesbadrenoceptormediatedairwayrelaxation
AT mariajelinic serelaxinelicitsbronchodilationandenhancesbadrenoceptormediatedairwayrelaxation
AT laurajparry serelaxinelicitsbronchodilationandenhancesbadrenoceptormediatedairwayrelaxation
AT chrishanssamuel serelaxinelicitsbronchodilationandenhancesbadrenoceptormediatedairwayrelaxation
AT janeelizabethbourke serelaxinelicitsbronchodilationandenhancesbadrenoceptormediatedairwayrelaxation